Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Bcr-abl1 Transcript Levels At 3 And 6 Months Are Better For Identifying Chronic Myeloid Leukemia Patients With Poor Outcome In Response To Second-line Second-generation Tyrosine Kinase Inhibitors After Imatinib Failure: A Report From A Single Institution.
Author: Ribeiro, Beatriz Felicio
Vergílio, Bruna Rocha
Miranda, Eliana Cristina Martins
Almeida, Maria Helena
Delamain, Marcia Torresan
da Silveira, Rosana Antunes
de Souza, Carmino Antonio
Albuquerque, Dulcinéia Martins
Dos Santos, Andrey
Duarte, Vagner Oliveira
Oliveira-Duarte, Gislaine Borba
Lorand-Metze, Irene
Pagnano, Katia Borgia Barbosa
Abstract: Early reduction of BCR-ABL1 transcript levels has been associated with improved outcome in chronic myeloid leukemia (CML) treatment. We evaluated 54 chronic-phase CML patients treated with imatinib who switched therapy to dasatinib (n = 33) or nilotinib (n = 21). BCR-ABL1 transcript levels were measured in peripheral blood using real-time quantitative PCR (RQ-PCR) every 3 months from the start of second-line treatment. Patients with BCR-ABL transcript levels >10% at 3 months and >1% at 6 months had significantly inferior progression-free (PFS) and event-free survival (EFS) than patients with RQ-PCR <10% at 3 months and <1% at 6 months (66 vs. 100%, p = 0.01, and 33 vs. 73%, p = 0.02, respectively). Patients with RQ-PCR <10% at 3 months and >1% at 6 months also had inferior PFS and EFS than patients with RQ-PCR <10% at 3 months and <1% at 6 months (48 vs. 100%, p = 0.002, and 25 vs. 73%, p < 0.0001, respectively). Two measurements of BCR-ABL levels were better than a single one to stratify chronic-phase CML patients as failure after second-line therapy. © 2015 S. Karger AG, Basel.
Citation: Acta Haematologica. v. 134, n. 4, p. 248-254, 2015-Jul.
Rights: fechado
Identifier DOI: 10.1159/000430835
Date Issue: 2015
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.